Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Tenn: Meningitis outbreak prompts investigation

By R&D Editors | October 2, 2012

Tennessee’s chief medical officer said Tuesday that state and federal health experts are investigating an outbreak of meningitis in which 14 people who received steroid injections contracted the infection and two of them died.

Dr. David Reagan, chief medical officer for the Tennessee Department of Health, said two more confirmed cases in the past 24 hours brought the total to 14. Authorities say all but one of those who contracted the infection had received steroid injections for back pain at a Nashville clinic.

The other case was reported in North Carolina in a patient who had received the same type of injection, authorities said.

Marion Kainer, an infectious diseases physician and epidemiologist with the Tennessee Health Department, said it’s still too early to pinpoint the source. But Kainer said three lots of injectable steroid used at a Nashville clinic between July 30 and Sept. 20 have been recalled by the manufacturer. The clinic, the Saint Thomas Outpatient Neurosurgery Center, voluntarily shut its doors Sept. 20.

“This is a serious illness, a serious disease,” Kainer said. “There is not a lot of experience treating it, but we’re getting the best advice possible.”

Officials haven’t identified the drug manufacturer or the city in North Carolina where one of the cases was reported. Reagan said that publicizing too much information at this time could negatively affect the investigation.

Centers for Disease Control and Prevention spokesman Curtis Allen said the agency is working with health departments in other states to determine whether other patients might be affected. He could not say how many people or clinics could potentially be affected nationally. In Tennessee there are about 900 people who received the injections at two clinics during the timeframe under investigation. No one from the second clinic has at this time been found to have contracted the disease, officials said.

Allen cautioned that while the injectable steroids were one thing the sickened patients had in common, there could also be other things in common, such as the anesthetic or the antiseptic, and the search for a cause is ongoing.

Of the 11 surviving patients in Tennessee, some are in critical condition while others are improving, Reagan said.

Health Department spokesman Woody McMillin said so far it has taken patients between seven days and 28 days to develop symptoms. Officials say new cases could yet be identified in coming days.

Related Articles Read More >

Parallel Bio’s embraces in-house drug development as FDA backs animal testing alternatives
R&D 100 Winner Spotlight: A closer look at Thermo Fisher Scientific’s trio of R&D 100 wins in 2025
Life sciences M&A hit $240B in 2025 as Big Pharma preps for patent cliffs
Hansoh Bio signs 32,000-sq.-ft. lab lease at Research Square in Rockville, MD
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2025 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

R&D 100 Awards
Research & Development World
  • Subscribe to R&D World Magazine
  • Sign up for R&D World’s newsletter
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE